Allogeneic stem-cell transplantation (SCT) with both myeloablative and reduced-intensity conditioning (RIC) is an effective therapy in AML/MDS. However, the relative merits of each may differ in different settings. To define the role of dose intensity, we analyzed SCT outcomes of 112 consecutive patients with AML/MDS. A total of 45 patients met eligibility criteria for standard myeloablative conditioning and were given intravenous-busulfan (12.8 mg/kg) and cyclophosphamide (ivBuCy). A total of 67 noneligible patients were given RIC with fludarabine and intravenous-busulfan (6.4 mg/kg, FB2, n ¼ 41) or a modified myeloablative regimen with fludarabine and myeloablative doses of intravenous-busulfan (12.8 mg/kg, FB4, n ¼ 26). The overall survival (OS) at 2 years was 50, 49 and 47% after ivBuCy, FB4 and FB2, respectively (P ¼ NS). Nonrelapse mortality was higher after ivBuCy, 22 vs 8% (P ¼ 0.05), but relapse rates were lower. Active disease at SCT was the most significant predictor of reduced survival in multivariable analysis (HR 4.5, P ¼ 0.0001). Myeloablative and RIC regimens had similar outcomes when leukemia was in remission at SCT; however, patients with active disease could only be salvaged by myeloablative conditioning. Among the latter, OS was 45% after ivBuCy but no FB2 recipient survived (P ¼ 0.02). Patients with active disease, ineligible for standard myeloablation, could tolerate modified myeloablation well; however, long-term outcome cannot be determined yet.
Introduction
Allogeneic hematopoietic stem-cell transplantation (SCT) is an effective, potentially curative treatment of advanced or high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SCT can cure leukemia by allowing the introduction of high-dose chemo-radiotherapy and by the induction of graftversus-leukemia effect (GVL) by immune competent cells in the graft. 1 Myeloablative conditioning may be associated with unacceptably increased toxicity in elderly, medically infirm or heavily pretreated patients. The introduction of SCT with reduced-intensity conditioning (RIC) allowed extension of allogeneic SCT to a much wider patient population by reducing the toxicity and exploiting the GVL effect as the primary curative approach. 2, 3 The importance of dose intensity has been shown in myeloablative SCT. More intensive conditioning is associated with a reduced risk for relapse after SCT, but does not translate to improved survival due to increased transplant-related toxicity. 4 Similarly, lower busulfan exposure, as determined by its area under the curve (AUC), is associated with a higher risk for graft rejection and relapse while the probability of organ toxicity increases with higher AUC. 5 The role of cytoreductive dose was also shown in RIC. De Lima et al. 6 reported a higher toxicity, but a lower relapse rate and a better overall survival after SCT with a RIC regimen consisting of fludarabine and melphalan than after a less-intensive nonmyeloablative regimen consisting of fludarabine, cytarabine and idarubicin. The relative merits of dose intensity may depend on patient and disease status at SCT. Reducing toxicity without compromising SCT efficacy could be a significant benefit to many patients but using a fully intensive conditioning despite increased toxicity may be necessary in others. In this study, we report our experience with 112 patients with AML and MDS using myeloablative or RIC regimens and correlate SCT outcomes with dose intensity in different settings.
Patients and methods

Patient eligibility
This study included patients with AML and MDS (all with excess of blasts). Patients were eligible for this study if they had AML at first remission but at high risk for relapse due to adverse cytogenetical abnormalities, a prior hematological disorder or prior chemotherapy for another malignancy, excessive blast count at presentation (4100 Â 10 9 /l) or slow response to induction therapy (two or more chemotherapy cycles required for remission induction) or at any status beyond first remission. Patients with MDS, or MDS transformed to AML, could receive SCT upfront with no prior chemotherapy if they had up to 50% marrow blasts and no peripheral blasts at the time of SCT. Patients were required to be free of marked organ dysfunction and to have an ECOG performance score of 0-2. Patients had to have an HLA-compatible related or unrelated donor willing to donate G-CSF-mobilized peripheral blood stem cells (the preferred requested option) or bone marrow. All patients gave written informed consent, and the study was approved by the institution review board.
Conditioning regimens
Patients considered eligible for myeloablative conditioning were given intravenous-busulfan (ivBu), 3.2 mg/kg daily in divided doses for 4 days followed by cyclophosphamide 60 mg/kg for 2 days (ivBuCy). Patients were considered not eligible for standard myeloablative therapy if they were of advanced age (over 55 years for matched sibling SCT or over 50 years for unrelated donor or mismatched SCT), if they had extensive prior therapy (more than two lines of prior chemotherapy or a prior autologous SCT), organ dysfunction, recent fungal infection or poor performance status. These patients were given fludarabine (total dose 150-160 mg/m 2 ) combined with ivBu 3.2 mg/kg daily for 2 days (total dose 6.4 mg/kg, FB2) or for 4 days (total dose 12.8 mg/kg, FB4). Based on prior experience with ivBu, busulfan plasma levels were not used for dose adjustments in any of these regimens. Patients with an unrelated or mismatched donor were also given antithymocyte globulin (ATG, Fresenius) at a total dose of 15 mg/kg. Phenytoin was administered before and until 24 h after completion of busulfan administration. Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporine A and a short course of methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6). GVHD prophylaxis was administered for 6 months after myeloablative conditioning, and tapered thereafter. Tapering of immune suppression was attempted earlier after RIC, starting at 3 months. Patients with minimal residual disease (MRD) after SCT had earlier tapering of immune suppression with both regimens and were eligible for donor lymphocyte infusions (DLI) if MRD was not cleared. 7 G-CSF was administered routinely from day þ 7 until engraftment.
Evaluation of response
Neutrophil and platelet engraftment were defined as the first of three days with an absolute neutrophil count (ANC) 40.5 Â 10 9 /l and the first of 7 days with an untransfused platelet count 420 Â 10 9 /l, respectively. Toxicity after SCT was graded by the National Cancer Institute (NCI) Common Toxicity Criteria (NCI, Bethesda, MD, USA). Acute and chronic GVHD were graded and staged by standard criteria. Chimerism was tested using FISH with X and Y chromosome probes in sex-mismatched transplants and with PCR analysis of microsatellite markers in sex-matched transplants. 8 Response and relapse were determined by standard hematologic criteria. Cytogenetical and molecular markers were used when applicable to determine MRD but were not used for determination of disease status. The use of immune interventions for treatment of MRD was not considered an evidence for relapse without standard hematologic criteria. 7 
Statistical analysis
The overall survival (OS) was calculated from the day of SCT until death or last follow-up. Disease-free survival (DFS) was calculated from the day of SCT until relapse, death or last follow-up. The probabilities of OS and DFS were estimated using the Kaplan-Meier method. 9 Relapse and nonrelapse mortality rates were estimated using cumulative incidence analysis, and were considered as competing risks. 10 The effect of various patient and disease categorical variables on survival probabilities was studied using the log-rank test. A Cox proportional hazard model was used to determine the significance of multiple variables in determining these outcomes.
Results
Patient and donor characteristics
The study included 112 consecutive patients with AML (n ¼ 95) and MDS (n ¼ 17) given SCT over a 5-year period. Thirty-nine of the patients with AML had 'disease that was secondary to prior' MDS (n ¼ 20), prior myeloproliferative disorder (n ¼ 6), therapy of prior malignancy (n ¼ 12; breast cancer -6, lymphoma -4, acute lymphoblastic leukemia -2) and prior renal transplant (n ¼ 1). Disease characteristics, status at SCT and donor source are outlined in Table 1 . The median age was 50 years (range, 17-70). In all, 54 patients had chemo-sensitive disease or untreated disease with less than 10% marrow blasts at SCT (remission group). A total of 58 patients had chemo-refractory disease or untreated disease with more than 10% blasts at SCT (active disease group). In all, 45 patients met eligibility criteria for standard myeloablative conditioning and were given ivBuCy. A total of 67 patients were not considered good candidates for standard myeloablative therapy, due to advanced age (n ¼ 56), organ dysfunction (n ¼ 8), poor performance status (n ¼ 8), recent fungal infection (n ¼ 7) or extensive prior therapy (n ¼ 9, including four patients with a history of prior autologous SCT); some patients had more than one excluding criteria. These patients were treated with a reduced-intensity regimen consisting of fludarabine and 2 days of ivBu (6.4 mg/kg, FB2, n ¼ 41) or a modified myeloablative conditioning regimen consisting of fludarabine and 4 days of ivBu (12.8 mg/kg, FB4, n ¼ 26). FB4 was introduced more recently and had a higher priority for enrollment over the last 2 years; however, FB2 was still open for enrollment during this later period. Follow-up is therefore shorter after FB4 than after FB2. Patients assigned to FB2 or FB4 had the same eligibility criteria by protocol; however, protocol assignment was not randomized and was affected to some degree by patient and physician discretion. Thus, older patients (especially those over 65 years) were given FB2 more often, while patients with active disease were given FB4 more often. Therefore, the median age of FB4 recipients was intermediate between ivBuCy and FB2, and a larger proportion of patients given FB2 were in remission and especially in CR1 (Table 1) . Patient assignment to ivBuCy was based on standard eligibility criteria and was not affected by disease status; however, this group had a relatively high proportion of patients with active disease.
In all, 59 donors were HLA-matched siblings. A total of 45 donors were unrelated volunteers; 31 were completely matched by high-resolution class I and class II HLA typing, three had 1 allele mismatch (A,B,C-one each), seven had 1 antigen mismatch (A-2, C-5) and four had multiple mismatches (class I -three patients, I þ II -one patient). Six donors were 1-antigen mismatched related (A-3, DR-3). Two donors were phenotypically HLA-matched parents and were analyzed with the mismatched related. Patients with an unrelated or mismatched donor over 50 years were excluded from ivBuCy; therefore, a higher proportion of FB2 recipients had alternative donors (Table 1) . In all, 108 donors donated peripheral-blood stem cells and only four donated bone marrow (all matched unrelated).
Engraftment and chimerism
A total of 105 patients achieved primary engraftment. Four patients died prior to engraftment and three had primary graft failure; one after ivBuCy (sibling donor) and two after FB2 (both with unrelated donors). Two additional patients had secondary graft rejection; one after FB4 and one after FB2. The median time to ANC 0.5 Â 10 9 /l was 13 days (range, 8-30 days). The median time to platelet 20 Â 10 9 /l was 14 days (range, 8-39 days). Eight patients died prior to achieving platelet transfusion independence. Four patients never dropped platelet count below 20 Â 10 9 /l, all conditioned with FB2. The median time to engraftment was not different between recipients of myeloablative and reduced-intensity regimens. However, among patients with normal neutrophil count at the start of conditioning, neutropenia was first detected on median day þ 4 after ivBuCy, and day þ 6 after FB2 (P ¼ 0.001), resulting in a median total of 8 days and 6 days of neutropenia, respectively (P ¼ 0.03). Patients conditioned with FB4 had values intermediate between these regimens. At 1 month after SCT, 82 of 105 patients with initial engraftment had complete donor chimerism and 23 had mixed chimerism, ranging in 18 patients from 90 to 99% donor, while five patients had mixed chimerism below 90%. Of the 23 patients with mixed chimerism, 12 converted spontaneously within the first 3 months to complete chimerism, eight have relapsed, one died prior to achieving complete chimerism and two are still mixed chimeras. Mixed chimerism at 1 month after SCT was more common after FB2 (30%) and FB4 (31%) than after ivBuCy (10%). All five patients with o90% donor at 1 month after SCT were given FB2 (three patients) or FB4 (two patients). However, at 3 months after SCT there was no difference between the regimens in chimerism status.
Toxicity and GVHD
NCI Grade III-V organ toxicity occurred in 52 patients (46%), 30 recipients of ivBuCy (67%), seven recipients of FB4 (27%) and 15 recipients of FB2 (37%, P ¼ 0.004 ivBuCy vs FB2/4, no difference between FB2 and FB4). NCI grade III and IV-V elevation of bilirubin and transaminases was a common finding, occurring in 43 and six patients, respectively. The peak level was 6-10 days after SCT, and it returned to a normal within 1-2 weeks. In only three patients could a clinical diagnosis of VOD be made by the Jones criteria:
11 two after ivBuCy and one after FB2; all were patients with refractory leukemia, and all three died. Grade IV-V hepatic toxicity occurred mostly in recipients of ivBuCy (five of six patients). Four patients had grade III renal toxicity (three after ivBuCy, one after FB4), five had grade III hemorrhagic cystitis (four ivBuCy, one FB4), four had thrombotic microangiopathy and one had reversible heart failure (ivBuCy). Some patients had organ toxicities in more than one system. Grade II-IV and III-IV acute GVHD occurred in 36 and 13 patients, with a cumulative incidence of 36% (95 C.I. 28-47%) and 14% (95 C.I. 8-23%), respectively. There was no difference in the rates of GVHD among recipients of the various regimens. However, patients having ivBuCy had a higher cumulative incidence of grade III/IV acute GVHD; 22% compared with 8% among recipients of FB2 and FB4 (P ¼ 0.02). Chronic GVHD occurred in 40 patients (16 extensive, 24 limited), with an overall cumulative incidence of 47% (95 C.I. 37-59%), 31% after FB2, 56% after FB4 and 56% after ivBuCy (P ¼ 0.02).
In all, nonrelapse mortality (NRM) occurred in 15 patients with a cumulative incidence of 14% (95 C.I. 9-22%) at 2 years after SCT. Nine patients died of complications related to acute GVHD, four died of organ toxicities, one died of sepsis prior to engraftment and one died of late graft rejection. There was a higher cumulative incidence of NRM among patients given ivBuCy than in patients given FB2 or FB4: 22, 8, and 8%, respectively ((P ¼ 0.05, Figure 1b) . Interestingly, excess NRM among recipients of ivBuCy was related mostly to increased risk Secondary AML, AML secondary to prior hematologic disorder or therapy-related. c Active disease, chemorefractory or previously untreated with 410% blasts at SCT, disease in remission, chemosensitive disease or previously untreated with o10% marrow blasts at SCT.
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A Shimoni et al of lethal GVHD. Excess of acute GVHD after ivBuCy was not related to the use of immune interventions. On the contrary, patients treated with this regimen had a longer period of immune suppression by protocol. Only one patient (FB4 recipient) was given DLI for MRD. Incidence of death due to regimen-related organ toxicity was very low among all three groups (two patients in ivBuCy and two in FB2). Patients with active disease had higher NRM than patients in remission, with a cumulative incidence of 21 and 6%, respectively (P ¼ 0.02). Age category and unrelated donor were not risk factors for NRM.
Outcome
SCT outcomes are outlined in Table 2 . With a median follow-up of 22 months (range, 2-64), 63 patients are alive and 49 have died. In all, 15 patients died of treatment-related complications and 34 died of disease relapse. The actuarial 2-year OS is 48% (95 C.I. 37-59%) (Figure 1a ). In all, 58 patients remain alive and disease-free, and 38 patients relapsed. The cumulative incidence of relapse is 41% (95 C.I. 32-53%). Relapse rates were not different in the three regimens, however, there was a trend for reduced relapse rates with ivBuCy ( Figure 1c ). Five relapsing patients are currently alive in CR 2, 3, 5, 10 and 25 months after chemotherapy and DLI. All others died. In all, the actuarial 2-year DFS is 45% (95 C.I. 33-54%). Table 3 outlines the univariable and multivariable analysis of factors influencing outcome. The status of disease at SCT was the most significant predictor of outcome. Patients in remission (as defined above) had an OS of 69% (95 C.I. 53-85%), whereas patients with active leukemia had an OS of 31% (95 C.I. 17-44%). Multivariable analysis confirmed the adverse effect of active disease (HR 4.5, P ¼ 0.0001) and poor-risk cytogenetics (HR 2.2 P ¼ 0.04), and a trend for adverse effect of SCT from unrelated donors (HR 1.8, P ¼ 0.08). The intensity of conditioning was not predictive of outcome (Figure 1a) . However, when the analysis of outcome is limited to patients with active disease the conditioning regimen used had a significant impact. OS of patients with active disease given the ivBuCy was 45%. None of the patients given reduced-intensity of ivBu (FB2) could be salvaged due to a very high risk of disease recurrence (Table 2, Figure 2a) . Some of the patients given modified myeloablative (FB4) could be salvaged, however follow-up is shorter than after the other regimens to allow definite comparison. Among patients in remission at SCT, there was no difference in OS between the various regimens with a nonstatistically significant trend for better survival with FB2 (Figure 2b) . Table 1 . OS ¼ projected overall survival at 2-year by Kaplan-Meyer analysis; rates are given with 95% confidence interval); DFS ¼ disease-free survival; NRM ¼ nonrelapse mortality (c.i. ¼ cumulative incidence of NRM calculated with relapse as considered competing risk). Cumulative incidence ratios among different regimens were compared using the log-rank test.
a Conditioning regimens defined in Table 1 . b In the analysis of NRM, FB2 and FB4 that had identical ratios were grouped together.
c Disease activity defined in Table 1. d P-value for ivBuCy vs FB2, no significant difference between ivBuCy and FB4.
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Discussion
Our data show that myeloablative (classical or modified) and RIC transplants are both effective therapies for AML and MDS. SCT after RIC was developed as a means to allow transplantation in patients not eligible for standard SCT due to advanced age or comorbidities. 2, 3 Initial studies showed the feasibility of this approach in small heterogeneous patient groups with various diseases. [12] [13] [14] [15] [16] Studies in single diseases followed and showed that RIC is effective in AML and MDS. 6, [17] [18] [19] There are no randomized studies comparing myeloablative and RIC transplants, as most groups, including ours, use standard myeloablative therapy for eligible patients and reserve RIC for the non-eligible. A few recent nonrandomized comparisons suggested, similar to our study, that outcome after RIC is grossly equivalent to that after myeloablative SCT. 20, 21 These studies showed a lower NRM, but a higher relapse rate, and equivalent survival with RIC. However, these studies included widely heterogeneous patient groups, with different diagnoses. We only studied patients with AML and MDS at different disease status and hypothesized that outcome after RIC and myeloablative SCT may differ in different settings. Notwithstanding that this too is a heterogeneous group and that this study is not a randomized or a direct case-control comparison, a few conclusions can be arrived at, and may be used to direct future studies. Figure 1 Outcomes after SCT by the conditioning regimen used. (a) Overall survival after SCT is similar after myeloablative conditioning with intravenous busulfan and cyclophosphamide (ivBuCy, n ¼ 45), after a modified myeloablative conditioning with fludarabine and myeloablative doses of intravenous busulfan (FB4, n ¼ 26) and after reduced-intensity conditioning (FB2, n ¼ 41). (b) Cumulative incidence of nonrelapse mortality (NRM) after SCT. NRM is higher after ivBuCy than after FB2 or FB4, P ¼ 0.05. (c) Cumulative incidence of relapse after SCT. A nonstatistically significant trend for lower relapse rate after ivBuCy. Table 1 ; MVA, multivariable analysis, factors with at least borderline statistical significance in the univariable analysis (Po0.2) were included in a Cox proportional hazard model; hazard ratios (HR) are presented with 95% confidence interval. Busulfan dose was also included in the model as it was the major purpose of the analysis.
Dose intensity in SCT A Shimoni et al RIC was able to achieve its first goal and extend SCT to a wider patient population. Over a 5-year period, more than half of the patients transplanted in our institution for AML/MDS were considered poor candidates for standard SCT and were given RIC or, more recently, FB4. These patients would have been differed from SCT in the past and would not have enjoyed its curative potential. This goal was achieved mostly because these new regimens were associated with a relatively low NRM: only 8%. FB2 is the prototype of the original RIC regimens. 12 Two groups have reported the use of fludarabine combined with myeloablative doses of ivBu 22 or targeted oral busulfan 23 as a means to reduce transplant-related toxicities. High-dose cyclophosphamide is closely associated with hepatic toxicity by depletion of glutathione, 24 and its substitution by fludarabine may reduce toxicity while maintaining antileukemia efficacy. The similar NRM rate in our study with FB2 and FB4 implies that the use of high-dose cyclophosphamide had a major contribution to NRM. NRM was limited because of low rates of both organ toxicity and severe GVHD.
The major contribution to reduced NRM after RIC and FB4 in this study was related to decreased risk for severe acute GVHD, 7-8 vs 22% (P ¼ 0.02). Chronic GVHD was also reduced, but this was not a common cause of NRM in both groups. GVHD continues to be a major obstacle to cure after RIC, but its incidence and severity in comparison with myeloablative SCT are still not well established. Couriel et al. reported that the incidence of acute and chronic GVHD is higher after myeloablative regimens. 25 Acute GVHD is related in part to cytokine release from damaged tissues, which amplifies the allogeneic response. 26 The limitation of mucosal injury with RIC and FB4 may therefore have reduced the incidence of acute GVHD. The more common occurrence of mixed chimerism early after SCT with FB2 and FB4 may also have limited the evolvement of acute GVHD. 7 The Seattle group showed that acute GVHD after nonmyeloablative conditioning was not reduced but rather delayed in time after SCT. 27 The major factor predicting OS is the status of disease at SCT. The EBMT reported OS after myeloablative SCT with sibling donors of 62% in CR1, 45% in CR2 and 23% in advanced disease. 28 OS rates are lower after unrelated donor SCT, and were 50, 28 and 7%, respectively, in a report by Sierra et al. 29 Similarly, Sayer et al. reported in a study of 113 patients conditioned with various RIC regimens that 1-year DFS was 49, 24 and 14% in patients with o5, 5-20, and 420% marrow blasts, at the time of SCT, respectively. 19 In our study, patients with active disease at SCT had an OS of 31% and a hazard ratio of 4.5 for adverse outcome compared with an OS of 69% in patients in remission at SCT. The merits of RIC were strictly dependent on the status of disease at SCT. Patients with disease in remission at SCT had a similar outcome whether conditioned with myeloablative regimens or RIC with a trend for better outcome with RIC. This is striking since FB2 recipients were selected based on higher risk for adverse outcome during SCT. The 2-year OS was 93% among 15 patients with high-risk AML in CR1 given RIC and none died of NRM. These results suggest that even patients who are eligible for myeloablative conditioning and are in remission may benefit from reducing toxicity with RIC without risking excess relapse rates. This hypothesis merits testing in a randomized prospective study. This improved outcome may change the approach to AML patients in CR1 with a donor and support early SCT with RIC. 30, 31 However, patients with active disease at SCT had very poor outcome with RIC, due to a very high risk for disease relapse. This observation is explained by relapse kinetics. The median time to relapse in patients with active disease was 2.1 months (range, 1-12) compared to 5.3 months (range, 1.5-22) for patients transplanted in remission (data not shown). RIC requires induction of GVL as the curative therapeutic tool, and this may require several months after transplantation to evolve. Patients with active disease may progress early after SCT, outpacing the development of effective GVL. However, a more intensive cytoreduction as achieved with myeloablative conditioning may allow sufficient time for GVL. RIC cannot be recommended, based on our data, for patients who cannot achieve remission with prior chemotherapy. Patients who were considered poor candidates for standard myeloablative conditioning could tolerate the modified myeloablative regimen with fludarabine substituting for high-dose cyclophosphamide relatively well, and some of these patients could be salvaged. However, the lower number of patients in this group and the shorter follow-up donot allow us to determine long-term outcome yet and to conclude whether this more intensive regimen will improve the poor outcome of patients with active leukemia given FB2. Other groups using a similar regimen did show that this modified , and this too merits further study in randomized studies. In all, RIC and myeloablative conditioning are both effective in the treatment of AML and MDS, however, their relative merits may be different based on disease activity at SCT, and response to prior chemotherapy.
